AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

By M. Rinella, B. Neuschwander‐Tetri, M. Siddiqui, M. Abdelmalek, S. Caldwell, D. Barb, D. Kleiner, R. Loomba. Hepatology, 2023

1,742 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/1abdeb673c1b083ee3b6908aa187c0914294fd1e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. R. Loomba
2. M. Rinella
3. Q. Anstee
4. K. Cusi
5. A. Sanyal
6. E. Bugianesi
7. Z. Younossi
8. Megan H. Bair-Merritt

In Epidemiology

1. M. Rinella
2. R. Loomba
3. K. Cusi
4. Q. Anstee
5. A. Sanyal
6. Vincent Wai-Sun Wong
7. E. Bugianesi
8. V. Ratziu

In Hepatology

1. R. Loomba
2. M. Rinella
3. K. Cusi
4. A. Sanyal
5. F. Kanwal
6. Q. Anstee
7. Z. Younossi

Citations in the corpus

• A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023, positive): “Moreover, this nomenclature process, in line with published guidance [21,28,29], is not advocating for the routine use of tests to con fi rm hepatic steatosis although, in reality, most, if not all, patients will usually have imaging at some point.”